ArticleAdvances in radiation oncology2026
Quality of Life and Toxicities Following Whole-Palm Versus Involved-Field Radiation Therapy for Dupuytren's Disease: A Substudy From a Randomized Trial.
Article in Advances in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The Dupuytren's disease Evaluation of Preventative or Adjuvant Radiation Therapy trial compared low-dose radiation therapy (LDRT) with observation for contracture prevention in early Dupuytren's disease. Guidelines vary regarding field selection due to concerns about toxicity in larger fields. In the LDRT arm of the prevention group, the permitted treatment fields were either whole-palm radiation therapy (WPRT) or involved-field radiation therapy (IFRT). This substudy compares quality-of-life and toxicity outcomes between WPRT and IFRT. Methods and Materials: This substudy analyzed 202 patients (202 treated hands) treated with LDRT (30 Gy in 10 fractions, split-course) in the Dupuytren's disease Evaluation of Preventative or Adjuvant Radiation Therapy trial prevention cohort. Quality of life was assessed using the pain intensity visual analog scale, Quick Disabilities of the Arm, Shoulder, and Hand, and Unité Rhumatologique des Affections de la Main at baseline and at 6, 12, and 36 months post-treatment. Toxicities were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.03. Results: Of 202 hands treated, 126 (62.4%) received WPRT and 76 (37.6%) received IFRT. Baseline characteristics were balanced between the groups. The pain intensity visual analog scale, Quick Disabilities of the Arm, Shoulder, and Hand, and Unité Rhumatologique des Affections de la Main scores did not differ significantly between the groups at any time point. LDRT was well tolerated with no grade 3 or higher toxicity observed. Acute toxicity was low grade, as expected, and more frequently reported following WPRT than IFRT. Persistent late effects were uncommon, with a <5% incidence of low-grade reduced sweating in the WPRT cohort. Conclusions: In early Dupuytren's disease, LDRT delivered using either WPRT or IFRT was well tolerated and associated with comparable patient-reported outcomes through 36 months. Acute toxicity was expected to be mild and more frequent following WPRT, whereas persistent late toxicity was infrequent, mild, and limited to a low rate of reduced sweating. Pending definitive data on the efficacy of LDRT in Dupuytren's disease, these findings support individualized field selection guided by disease distribution, clinical judgment, and patient preference.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.